Author/Authors :
فرخي، شكرالله نويسنده 1Department of Immunology and Allergy, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran Farrokhi, Shokrollah , روانبد، محمدرضا نويسنده , , اميري ، شهرام نويسنده , , نبي پور، ايرج نويسنده nabipour, iraj , اسدي ، مجيد نويسنده asadi, majid
Abstract :
The principle of cancer immunotherapy includes various methods of manipulations to influence immune responses against
tumors in both humans and animals. This advanced technology of hybridoma production provided the necessary skills to
efficiently produce highly specific monoclonal antibodies (mAb). Radioactively-tagged antibodies which are applied in
radioimmunotherapy (RIT), can target adjacent cells and may not require immune function. This study highlights the
mechanism and the effect of action of radioimmunotherapic agents, especially two applied agents including 90Yibritumomab
tiuxetan and 131I-tositumomab that are approved by Food and Drug Administration (FDA) for treatment of
some cancers
